United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2012_register executive 2014-05-29 article Notices D09002ee1c7fd7f6e D09002ee1c7fd810b United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in US Patent application 61/535,668 entitled "Pseudomonas Exotoxin A with Less Immunogenic B Cell Epitopes" [HHS Ref. E-263-2011/0-US-01], US Patent application 61/495,085 entitled "Pseudomonas Exotoxin A with Less Immunogenic T Cell Epitopes" [HHS Ref. E-174-2011/0-US-01], US Patent application 61/483,531 entitled "Recombinant Immunotoxin Targeting Mesothelin" [HHS Ref. E-117-2011/0-US-01], U.S. Patent Application 61/241,620 entitled "Development of an Immunotoxin in Which All B-Cell Epitopes Have Been Removed and Which Has High Cytotoxic Activity" [HHS Ref. E-269-2009/0-US-01], U.S. Patent Application 60/969,929 entitled "Deletions in Domain II of Pseudomonas Exotoxin A That Reduce Non-Specific Toxicity" [HHS Ref. E-292-2007/0- US-01], U.S. Patent Application 60/703,798 entitled "Mutated Pseudomonas Exotoxins with Reduced Antigenicity" [HHS Ref. E-262-2005/ 0-US-01], U.S. Patent Application 60/160,071 entitled "Immunoconjugates Having High Binding Affinity" [HHS Ref. E-139-1999/ 0-US-01], U.S. Patent Application 60/067,175 entitled "Antibodies, Including Fv Molecules, and Immunoconjugates Having High Binding Affinity for Mesothelin and Methods for Their Use" [HHS Ref. E-021- 1998/0-US-01], U.S. Patent Application 60/010,166 entitled "Molecular Cloning of Mesothelin, a Differentiation Antigen Present on Mesothelium, Mesotheliomas and Ovarian Cancers" [HHS Ref. E-002-1996/ 0-US-01], PCT Application PCT/US97/00224 entitled "Mesothelin Antigen and Methods and Kits for Targeting It" [HHS Ref. E-002-1996/1-PCT-01], U.S. Patent 5,747,654 entitled "Recombinant Disulfide-Stabilized Polypeptide Fragments Having Binding Specificity" [HHS Ref. E-163- 1993/0-US-01], PCT application PCT/US96/16327 entitled "Immunotoxin Containing A Disulfide-Stabilized Antibody Fragment" [HHS Ref. E-163- 1993/2-PCT-01], and all continuing applications and foreign counterparts, to Hoffman-La Roche, Inc. The patent rights in these inventions have been assigned to and/or exclusively licensed to the Government of the United States of America. The prospective exclusive license territory may be worldwide, and the field of use may be limited to: 77 FR 8263 https://www.govinfo.gov/app/details/FR-2012-02-14/2012-3410 2012-3410 fr14fe12-84 4140-01-P https://www.govinfo.gov/app/details/FR-2012-02-14/2012-3410 https://www.govinfo.gov/content/pkg/FR-2012-02-14/html/2012-3410.htm https://www.govinfo.gov/content/pkg/FR-2012-02-14/pdf/2012-3410.pdf 2 p. 8263 8264 77 FR 8263 Prospective Grant of Exclusive License: The Development of Anti-mesothelin Targeted Immunotoxins for the Treatment of Cancer; Federal Register Vol. 77, Issue NOTICE 2012-3410 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2012-03-15 4140-01-P 2012-3410 Notice.

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in US Patent application 61/535,668 entitled "Pseudomonas Exotoxin A with Less Immunogenic B Cell Epitopes" [HHS Ref. E-263-2011/0-US-01], US Patent application 61/495,085 entitled "Pseudomonas Exotoxin A with Less Immunogenic T Cell Epitopes" [HHS Ref. E-174-2011/0-US-01], US Patent application 61/483,531 entitled "Recombinant Immunotoxin Targeting Mesothelin" [HHS Ref. E-117-2011/0-US-01], U.S. Patent Application 61/241,620 entitled "Development of an Immunotoxin in Which All B-Cell Epitopes Have Been Removed and Which Has High Cytotoxic Activity" [HHS Ref. E-269-2009/0-US-01], U.S. Patent Application 60/969,929 entitled "Deletions in Domain II of Pseudomonas Exotoxin A That Reduce Non-Specific Toxicity" [HHS Ref. E-292-2007/0- US-01], U.S. Patent Application 60/703,798 entitled "Mutated Pseudomonas Exotoxins with Reduced Antigenicity" [HHS Ref. E-262-2005/ 0-US-01], U.S. Patent Application 60/160,071 entitled "Immunoconjugates Having High Binding Affinity" [HHS Ref. E-139-1999/ 0-US-01], U.S. Patent Application 60/067,175 entitled "Antibodies, Including Fv Molecules, and Immunoconjugates Having High Binding Affinity for Mesothelin and Methods for Their Use" [HHS Ref. E-021- 1998/0-US-01], U.S. Patent Application 60/010,166 entitled "Molecular Cloning of Mesothelin, a Differentiation Antigen Present on Mesothelium, Mesotheliomas and Ovarian Cancers" [HHS Ref. E-002-1996/ 0-US-01], PCT Application PCT/US97/00224 entitled "Mesothelin Antigen and Methods and Kits for Targeting It" [HHS Ref. E-002-1996/1-PCT-01], U.S. Patent 5,747,654 entitled "Recombinant Disulfide-Stabilized Polypeptide Fragments Having Binding Specificity" [HHS Ref. E-163- 1993/0-US-01], PCT application PCT/US96/16327 entitled "Immunotoxin Containing A Disulfide-Stabilized Antibody Fragment" [HHS Ref. E-163- 1993/2-PCT-01], and all continuing applications and foreign counterparts, to Hoffman-La Roche, Inc. The patent rights in these inventions have been assigned to and/or exclusively licensed to the Government of the United States of America. The prospective exclusive license territory may be worldwide, and the field of use may be limited to:

Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before March 15, 2012 will be considered. Exclusive Licenses: Development of Anti-Mesothelin Targeted Immunotoxins for the Treatment of Cancer , lambertsond@od.nih.gov Vol. 77, no. 30 Office of the Federal Register, National Archives and Records Administration 2012-02-14 continuing daily deposited born digital 633 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2012-02-14 P0b002ee1892c66ec 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr14fe12 https://www.govinfo.gov/app/details/FR-2012-02-14 https://www.govinfo.gov/content/pkg/FR-2012-02-14/pdf/FR-2012-02-14.pdf https://www.govinfo.gov/content/pkg/FR-2012-02-14/xml/FR-2012-02-14.xml fdlp 8089 8715 DGPO 2014-05-29 2024-06-03 FR-2012-02-14 machine generated eng FR FR-2012-02-14 77 30